SONNSonnet BioTherapeutics Holdings, Inc.

SONN Stock Price, Valuation & Chart | Sonnet BioTherapeutics Holdings, Inc.

Compare

$1.260-1.84 (-59.35%)

At close · 02 Dec 2025, 09:00 pm

Sector: Healthcare Industry: Biotechnology SONN intrinsic value SONN calculated fair value vs price

Overview Financials Dividends Ratios

SONN Historical price chart

SONN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization8.43M

PE Ratio-0.18

EPS-6.82

Trading Volume10.43M

Today's High/Low3.23/1.26

Dividend Yield0.00

52 Week High/Low19.3/1.08

Shares Outstanding6.69M

SONN Financial Statement

SONN Analyst ratings

SONN Analysis & performance metrics

SONN Company profile

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The…

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate…

SONN Management team

Name

Position

Donald J. Griffith CPA, CPACFO

Chief Financial Officer, Financial Controller & Director

Manuel Dafonseca

Head of Clinical Operations

Stephen J. McAndrew Ph.D.

President & Chief Business Officer

Richard T. Kenney FACP, M.D.

Chief Medical Officer

John K. Cini Ph.D.

Chief Scientific Officer & Co-Founder

Raghu RaoCEO

Interim Chief Executive Officer & Director

Susan Dexter

Chief Technical Officer

Gael Hedou Ph.D.COO

Chief Operating Officer

Name

Position

Donald J. Griffith CPA, CPACFO

Chief Financial Officer, Financial Controller & Director

Manuel Dafonseca

Head of Clinical Operations

Stephen J. McAndrew Ph.D.

President & Chief Business Officer

Richard T. Kenney FACP, M.D.

Chief Medical Officer

John K. Cini Ph.D.

Chief Scientific Officer & Co-Founder

Raghu RaoCEO

Interim Chief Executive Officer & Director

Susan Dexter

Chief Technical Officer

Gael Hedou Ph.D.COO

Chief Operating Officer

Management Team

Donald J. Griffith CPA, CPACFO

Chief Financial Officer, Financial Controller & Director

Manuel Dafonseca

Head of Clinical Operations

Stephen J. McAndrew Ph.D.

President & Chief Business Officer

Richard T. Kenney FACP, M.D.

Chief Medical Officer

John K. Cini Ph.D.

Chief Scientific Officer & Co-Founder

Raghu RaoCEO

Interim Chief Executive Officer & Director

Susan Dexter

Chief Technical Officer

Gael Hedou Ph.D.COO

Chief Operating Officer

Management

Donald J. Griffith CPA, CPACFO

Chief Financial Officer, Financial Controller & Director

Manuel Dafonseca

Head of Clinical Operations

Stephen J. McAndrew Ph.D.

President & Chief Business Officer

Richard T. Kenney FACP, M.D.

Chief Medical Officer

John K. Cini Ph.D.

Chief Scientific Officer & Co-Founder

Raghu RaoCEO

Interim Chief Executive Officer & Director

Susan Dexter

Chief Technical Officer

Gael Hedou Ph.D.COO

Chief Operating Officer

Total 8 executives

SONN Frequently asked questions

What is Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock Price?

Current stock price of Sonnet BioTherapeutics Holdings, Inc. (SONN) stock is $1.260. The stock price is -59.35% lower in the session. The intraday range can be seen from this page. Volume of Sonnet BioTherapeutics Holdings, Inc. (SONN) stock is 10.43M.

Last updated at 02 Dec 2025, 09:00 pm.

Why is the Sonnet BioTherapeutics Holdings, Inc. (SONN) stock price going up or down today?

The stock price of Sonnet BioTherapeutics Holdings, Inc. (SONN) can change with earnings, company news, and overall market sentiment. Sonnet BioTherapeutics Holdings, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Sonnet BioTherapeutics Holdings, Inc. stock expensive at its current price?

Whether Sonnet BioTherapeutics Holdings, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for SONN on this page is -0.18. EPS on this page is -6.82. Compare those figures with peers and growth expectations before deciding if the current Sonnet BioTherapeutics Holdings, Inc. price is justified.

How has the stock price of Sonnet BioTherapeutics Holdings, Inc. (SONN) performed historically?

Historical performance for Sonnet BioTherapeutics Holdings, Inc. (SONN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how SONN reacted to past earnings and market events.

Should I buy Sonnet BioTherapeutics Holdings, Inc. (SONN) stock, at this price?

Buying Sonnet BioTherapeutics Holdings, Inc. (SONN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.